Brittany Barham
Family · Greenville, SCNPI 1356894000
Payments from drug & device makers
Across 161 payments — averaging $15.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$454
- Novo Nordisk$430
- Lilly USA, LLC$324
- Boehringer Ingelheim$199
- AstraZeneca$178
- Takeda Pharmaceuticals U.S.A., Inc.$160
- plus $677 from 21 others
What the payments were for
- Food & beverage$2,423100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 39 | $454 |
| Novo Nordisk | 28 | $430 |
| Lilly USA, LLC | 23 | $324 |
| Boehringer Ingelheim | 13 | $199 |
| AstraZeneca | 10 | $178 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $160 |
| Pfizer | 7 | $115 |
| Amgen | 5 | $79 |
| Esperion Therapeutics, Inc. | 5 | $69 |
| Corium, LLC | 4 | $55 |
| Inari Medical, Inc. | 1 | $30 |
| Bayer | 2 | $29 |
| IBSA Pharma Inc. | 2 | $28 |
| Lundbeck LLC | 1 | $28 |
| Shield Therapeutics Inc | 1 | $24 |
| Astellas Pharma US Inc | 1 | $23 |
| Johnson & Johnson | 1 | $23 |
| Mayne Pharma Commercial LLC | 1 | $23 |
| Novartis | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| GSK | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Neos Therapeutics, LP | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
| Genentech USA, Inc. | 1 | $6 |
How this compares
$2,423 in reported general payments places this provider in the 80th percentile of 3,248 family providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 16 | $20,661 |
| MounjaroTirzepatide | 15 | $17,512 |
| JardianceEmpagliflozin | 17 | $13,779 |
| Duloxetine Hcl | 28 | $754 |
| Rosuvastatin Calcium | 53 | $708 |
| Gabapentin | 43 | $615 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 25 | $524 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 16 | $520 |
| Metformin Hcl | 40 | $504 |
| Estradiol | 11 | $410 |
| Glipizide ErGlipizide | 15 | $393 |
| Bupropion XlBupropion Hcl | 12 | $388 |
| Levothyroxine Sodium | 53 | $370 |
| Atorvastatin Calcium | 31 | $322 |
| Omeprazole | 23 | $286 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $430 | $20,66116 claims |
| Lilly USA, LLCMounjaro | $324 | $17,51215 claims |
| Boehringer IngelheimJardiance | $199 | $13,77917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,248 family providers in South Carolina.
Other family in Greenville
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Carrie HendersonGreenville$91K
- Michelle StrongGreenville$55K
- Melissa BrownlowGreenville$20K
- Sarah McNightGreenville$15K
- Melissa MotesGreenville$13K
- Matthew KeatonGreenville$10K
- Kara Cooper GilmerAnderson$127K
- Jessica BellEasley$96K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.